David S S, Huggins G R, Garcia C R, Busacca C
Fertil Steril. 1979 Mar;31(3):278-81.
Five milligrams of the steroid R2323 (13 beta-ethyl-17 alpha-ethynyl-17-hydroxygona-4,9,11-trien-3-one (R2323) were administered orally once weekly to 28 subjects for a total of 138 treatment cycles. No pregnancies occurred. The predominant side effects were irregular vaginal bleeding, headache, weight gain, and acne. Administration of the drug was stopped by the investigator in four patients (14%) because of the onset of headaches. Four patients discontinued the drug for other reasons. In 8 of 26 subjects (31%), endometrial biopsy in the third treatment cycle showed secretory endometrium. This suggests a variable central suppression with the 5-mg dose schedule. Patients were enthusiastic about the once-weekly oral administration. This contraceptive may be useful in a select group of women.
对28名受试者每周口服一次5毫克甾体R2323（13β-乙基-17α-乙炔基-17-羟基-4,9,11-三烯-3-酮（R2323），共进行138个治疗周期。未发生妊娠。主要副作用为不规则阴道出血、头痛、体重增加和痤疮。4名患者（14%）因出现头痛，研究者停止了该药物给药。4名患者因其他原因停药。26名受试者中有8名（31%）在第三个治疗周期的子宫内膜活检显示为分泌期子宫内膜。这表明5毫克剂量方案的中枢抑制作用存在差异。患者对每周一次的口服给药方式很满意。这种避孕药可能对特定的女性群体有用。
